Scientists’ Risky Wagers on Once-Untreatable Tumors Now Reshape Biotech Fortunes

Two veteran researchers placed enormous personal and financial stakes on ideas long dismissed as hopeless. Their convictions have begun to deliver results that few anticipated. One backed a personalized vaccine approach. The other poured resources into cracking proteins that had repelled drug hunters for decades. Both bets now fuel surging valuations and tangible patient gains.

Tal Zaks, who served as chief medical officer at Moderna, described his commitment in stark terms. He took “a very large financial bet just based on first principle beliefs,” he told Business Insider. Zaks understood that success would hinge on precise trial design and the right molecular architecture. Early data from mice or small human studies offered little guidance. Faith in the underlying biology carried the day.

That conviction found validation this August. Moderna and partner Merck reported positive Phase 3 results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients. The news sent Moderna’s shares soaring 177% in a single session, reaching $174 each. The outcome marked the first late-stage success for such a tailored vaccine. It also underscored how mRNA technology, once focused on infectious disease, now extends into oncology with measurable impact.

But Zaks’ story forms only part of a broader pattern. Across biotech, efforts once labeled futile have started to pay dividends. And the numbers reflect it. Analysts project blockbuster potential for several of these programs.

Targeting the proteins that evaded capture

Greg Verdine took an even earlier gamble. In 2012, after years of fundraising struggles, he secured $125 million to pursue a concept inspired by nature. No drug candidate existed yet. The path forward remained hazy. Verdine, a chemist, believed certain molecular glues could bind to previously inaccessible targets. His persistence laid groundwork for approaches now reaching patients.

Revolution Medicines, the Silicon Valley company tied to this line of inquiry, secured FDA approval in late August for a pill treating late-stage prostate cancer. The molecular glue targets so-called undruggable cancer drivers. Weeks earlier, the same company delivered striking data in pancreatic cancer. Its oral RAS(ON) multi-selective inhibitor, daraxonrasib (also known as Rasonque), nearly doubled median overall survival in previously treated metastatic patients.

In the Phase 3 RASolute 302 trial, those receiving daraxonrasib lived a median of 13.2 months. Participants on standard chemotherapy survived 6.7 months. The hazard ratio stood at 0.40, with strong statistical significance. Progression-free survival improved from 3.5 to 7.3 months. Response rates reached 33.2% versus 11.8%. Serious adverse events proved lower with the new pill. The New York Times described the advance as the first to substantially extend lives in pancreatic cancer trials. Researchers had long viewed KRAS mutations, present in nearly all such tumors, as a “greasy ball” impervious to attack.

Former Nebraska Sen. Ben Sasse, diagnosed with stage 4 pancreatic cancer, called the treatment a “miracle” worker. It reduced his pain and shrank tumors dramatically. “I have much, much less pain than I had four months ago, when I was diagnosed,” Sasse told “60 Minutes” in April, per reports in Business Insider.

But the implications stretch further. The same mechanism shows promise against lung and colon cancers, which together rank among the top causes of cancer death. Marina Pasca di Magliano, a University of Michigan researcher, noted that almost everybody once thought drugs against KRAS would prove impossible. That consensus has crumbled.

Wall Street responded with enthusiasm. BioPharma Dive, reporting on Sept. 3, highlighted a $39,800 monthly list price for Rasonque, higher than some forecasts. Evercore ISI analysts lifted peak sales estimates for pancreatic cancer alone to $15.1 billion by 2034. They see potential for $20.8 billion annually if approvals expand to additional tumor types. RBC Capital Markets cited “significant demand,” noting more than 2,000 patients had already received the drug via compassionate use programs even before full marketing began.

Revolution Medicines raised billions to fund its pipeline, including a $2 billion agreement with Royalty Pharma. The company maintains multiple Phase 3 trials, including front-line pancreatic studies and combinations in non-small cell lung cancer. Its independence from acquisition attempts now looks prescient. Success has validated years of patient capital allocation.

So what explains the sudden convergence of these once-fringe ideas? Improved understanding of tumor biology plays a central role. Better trial designs reduce noise. And advances in delivery, whether mRNA or sophisticated small molecules, allow precise interference with cancer pathways. Yet the human element remains decisive. Zaks and Verdine, among others, refused to accept conventional limits. Their financial and scientific commitments created the conditions for progress.

Recent coverage reinforces the momentum. On Sept. 4, Al Majalla detailed how Merck and Moderna’s melanoma data added nearly $45 billion to Moderna’s market value in one day. The piece also noted broader oncology spending hitting $252 billion in 2024, with expectations of $441 billion by 2029. Venture investors have taken notice. Over $9 billion flowed to biotech firms in the first half of 2026, much of it directed toward companies with assets already in human testing.

Other players pursue similar targets. Immuneering, Actuate Therapeutics and Erasca work on RAS-related inhibitors, hoping to match or exceed Revolution’s tolerability and efficacy. BioSpace reported in May that these competitors see opportunity to build on the “miracle” results. Truist analysts described Revolution as evolving into a major oncology revenue generator.

Analysts at GeneOnline, in a June 22 article, outlined Revolution’s additional registrational programs. These include first-line pancreatic trials and a G12D-selective inhibitor for lung cancer. The company now holds substantial cash reserves to execute without immediate dilution pressure.

Still, challenges persist. Pricing debates will intensify as these therapies reach wider populations. Pancreatic cancer patients, though desperate for options, represent a fraction of the total addressable market. Manufacturing personalized vaccines at scale demands sophisticated logistics. And competition among RAS inhibitors could fragment market share.

Even so. The shift feels unmistakable. Treatments dismissed as impossible now sit inside regulatory pathways or on pharmacy shelves. Patients who once faced months of decline report extended time with reduced pain. Investors who funded the long shots watch their positions multiply.

Zaks captured the spirit well. Success required asking the right questions at the right moment and committing capital despite scant early proof. Verdine similarly bet on a hazy vision grounded in chemical first principles. Their examples illustrate a larger truth in drug development. Some breakthroughs arrive only after repeated failure and unwavering belief. This year, several such long-held convictions have started to convert into clinical reality. The biotech sector, and the patients it serves, stand to benefit for years ahead.